SS-31 Peptide Guide: Benefits, Dosage & How It Works

Almost every peptide in the longevity world lives in the same gray zone. Interesting mechanism, a pile of rat studies, zero regulatory validation, and a vendor page telling you it changes everything.

SS-31 broke out of that zone. On September 19, 2025, the FDA approved this exact molecule as a prescription drug. Not a similar compound. Not a derivative. The same tetrapeptide that gets sold as SS-31 in research vials, approved under the name FORZINITY, became the first mitochondria-targeted therapeutic in history to clear the FDA.

BrainFlow Newsletter

Want to live forever? Thought so.

One email every Friday — the best on supplements, longevity, and biohacking, cut down to what actually works. No spam. Unsubscribe anytime.

Email address Subscribe

No spam. Your privacy is important to us.

That is a big deal, and it is also where most articles about SS-31 go off the rails. The approval is narrow. It covers one ultra-rare genetic disease called Barth syndrome, in patients over 30 kilograms, on an accelerated pathway that still requires a confirmatory trial. It does not mean SS-31 is approved for fatigue, aging, or performance. It does not make the vial you buy online the same product as the pharmaceutical.

So the real story is more interesting than the hype and more encouraging than the skeptics let on. SS-31 does something no supplement on your shelf does. It targets cardiolipin, a specific molecule inside the inner wall of your mitochondria, and it concentrates there at up to 5,000 times the surrounding concentration. That precision is why it works when it works, and it is why a handful of big trials still missed their targets.

This guide covers all of it. What SS-31 is, why cardiolipin matters more than any other word in this article, how the mechanism works in plain English, what the clinical trials showed including the ones that failed, how it is dosed, what the side effects look like, how it stacks against MOTS-c and NAD+, and where to get material worth putting in your body.

If you already know the story and just want a vial, Everest Peptides SS-31 is where we send readers. Third-party tested by Freedom Diagnostics, on sale at $44.99, and code BRAINFLOW takes another 10% off that, putting you around $40. Everyone else, keep reading.

Short version of what draws people to SS-31:

• It targets cardiolipin directly, the structural lipid that organizes your mitochondrial energy machinery
• It concentrates 1,000 to 5,000-fold at the inner mitochondrial membrane instead of scattering through the body
• It restored aged mouse mitochondria to youthful energy output within one hour of a single dose
• Its molecule is FDA-approved for Barth syndrome, the first mitochondria-targeted drug ever cleared
• It works whether or not membrane potential is intact, which matters because sick mitochondria lose that potential
• Trial safety has been solid, with injection-site reactions as the dominant complaint

What Is SS-31?

SS-31 is a synthetic peptide made of four amino acids. Four. That is it. In peptide terms it is a tetrapeptide, which makes it tiny next to something like BPC-157 (fifteen amino acids) or TB-500 (forty-three).

The sequence is D-Arg-Dmt-Lys-Phe-NH2. Three parts of that are worth understanding because they explain everything the molecule does.

The “D-Arg” is D-arginine, a mirror-image version of the normal amino acid. Your enzymes are built to chew up the standard form, so flipping it makes the peptide much harder to degrade. The “Dmt” is 2,6-dimethyltyrosine, a modified tyrosine that acts as a built-in antioxidant, scavenging reactive oxygen species right where they are made. And the alternating pattern of positively charged and aromatic residues gives the molecule a net 3+ charge with a greasy face, which is the combination that lets it slip through cell membranes and then stick hard to the one place it is designed to go.

The name comes from its inventors. Hazel Szeto at Weill Cornell and Peter Schiller at the Institut de recherches cliniques de Montréal designed a series of peptides together, and this was number 31 in the run. Hence Szeto-Schiller peptide 31, shortened to SS-31.

The origin story is a good one. The Szeto-Schiller series started out as opioid research, not mitochondrial research. As the team modified the structure, they knocked opioid receptor affinity down roughly 2,000-fold, and what was left behind turned out to have a completely different and far more useful talent: it went straight to the mitochondria. Szeto founded Stealth BioTherapeutics in 2006 to develop it as a drug.

The naming confusion around this compound is the worst in the peptide space, and it costs people real money. Sorting it out is the single most useful thing this article can do for you.

Every one of those names points at the same tetrapeptide. Molecular weight is about 640, formula C32H49N9O5, CAS number 736992-21-5. When a vendor page and a clinical trial appear to disagree, it is almost always because one is saying “SS-31” and the other is saying “elamipretide” about the same thing.

SS-31 vs Elamipretide: The Distinction That Matters

Same molecule does not mean same product. There are four tiers here, and conflating them is the most common mistake online.

FORZINITY is a pharmaceutical made under drug manufacturing standards, supplied at 80 mg/mL in single-patient vials, prescribed for Barth syndrome. Compounded elamipretide is prepared by licensed pharmacies for physicians in some wellness practices. Clinical-trial elamipretide is what the studies used. And research-grade SS-31 is a lyophilized powder sold for laboratory use, with quality that depends entirely on the vendor’s testing.

The molecule is identical across all four. The manufacturing oversight, purity verification, sterility, and legal status are not. When someone says “SS-31 is FDA-approved,” they are collapsing four things into one, and that is wrong in a way that matters.

Cardiolipin: The Word That Explains Everything

Skip this section and nothing else in the article makes sense. Read it and you will understand SS-31 better than most people selling it.

Your mitochondria produce roughly 90% of your body’s energy. The currency is ATP, and the factory floor is the inner mitochondrial membrane, which is folded into dense pleats called cristae. Those folds are not decorative. They pack in the machinery.

The machinery is the electron transport chain, a series of protein complexes that pass electrons down a line like a bucket brigade. Each handoff pumps protons across the membrane, building up a charge gradient. That gradient drives a molecular turbine called ATP synthase, which spins and cranks out your energy. This whole process is oxidative phosphorylation.

It is not a clean process. Some electrons leak, react with oxygen, and become reactive oxygen species. A little is normal signaling. Too much is oxidative stress, and it damages proteins, lipids, and DNA.

Now the important part. Holding all of that machinery in place is a phospholipid called cardiolipin, found almost nowhere in your body except the inner mitochondrial membrane. Cardiolipin anchors the electron transport chain complexes, keeps them clustered into efficient supercomplexes, and gives the cristae their shape.

Cardiolipin is like the structural wiring that keeps the mitochondrial power system organized. When the wiring is intact, electrons flow where they should and energy production is efficient. When the wiring degrades, the whole system gets sloppy: more leak, more oxidative stress, less ATP.

And cardiolipin is unusually vulnerable. It sits right next to where reactive oxygen species are generated, and its fatty acid tails are exactly the kind that oxidize easily. Cardiolipin gets attacked by the very process it supports.

There is a vicious cycle here that is worth knowing. A protein called cytochrome c normally sits on cardiolipin doing its job as an electron carrier. When cardiolipin gets oxidized, cytochrome c changes character and turns into a peroxidase, an enzyme that attacks cardiolipin further. Damaged wiring creates a saboteur that damages more wiring. This loop is implicated in aging, heart failure, kidney injury, muscle dysfunction, and neurodegeneration.

This is why “mitochondrial support” on a supplement label is usually meaningless and SS-31 is not. Most compounds throw antioxidants at the general area or supply raw materials. SS-31 goes to the wiring and stabilizes it.

How SS-31 Works

SS-31 crosses into cells without needing a transporter and without burning energy, then goes hunting for cardiolipin. Because cardiolipin lives almost exclusively in the inner mitochondrial membrane, the peptide effectively has a homing address.

The concentration numbers are what make this remarkable. The foundational 2004 paper in the Journal of Biological Chemistry reported that these peptides cross the plasma membrane in an energy-independent, non-saturable way and accumulate 1,000 to 5,000-fold at the inner mitochondrial membrane. Take a step back and appreciate that. A compound you inject under the skin ends up concentrated thousands of times over inside one specific membrane of one specific organelle.

Better still, that uptake does not depend on mitochondrial membrane potential. Many mitochondria-targeted compounds ride the membrane’s electrical charge to get in, which means they work worst in the damaged mitochondria that need help most. SS-31 does not have that problem.

Once bound to cardiolipin, several things follow. Szeto’s own review in the British Journal of Pharmacology lays out the core of it: SS-31 keeps cytochrome c locked into its electron-carrier role and blocks the peroxidase behavior that drives the damage loop. It stabilizes cristae structure. It helps the electron transport chain complexes stay organized, which improves electron flow and cuts down on leak.

The downstream effects follow from that. ATP production improves. Reactive oxygen species drop at the source rather than being mopped up after the fact. The mitochondrial permeability transition pore, a stress-triggered channel that can push a cell into apoptosis, becomes harder to open. Research published in the Journal of the American Society of Nephrology showed SS-31 re-energizing ischemic mitochondria specifically through its cardiolipin interaction.

The honest caveat belongs here rather than buried at the bottom. A beautiful mechanism is not a promise of results. SS-31 does exactly what the biochemistry says it does, and several large human trials still failed to hit their targets. Both facts survive together, and the rest of this article explains why.

SS-31 Benefits: What Holds Up and What Does Not

SS-31 has a stronger research backbone than most peptide trends because elamipretide has been through real clinical trials. The open question was never whether the mechanism is interesting. It is which human outcomes are strong enough to matter. Let us go benefit by benefit and grade each one.

Mitochondrial Energy and ATP Production

The core claim, and the best-supported one mechanistically. In isolated mitochondria and animal tissue, SS-31 consistently improves ATP output in cells that were struggling. The nuance that keeps getting lost: it does the most in dysfunctional mitochondria and comparatively little in healthy young ones. If your mitochondria are fine, there may not be much to fix. Grade: strong preclinical, mechanistic in humans.

Aging and Age-Related Decline

This is the section biohackers care about most and it deserves an honest treatment. The animal data is close to astonishing. A 2013 study in Aging Cell found that a single treatment restored in-vivo mitochondrial energetics in aged mice to youthful levels within one hour, and eight days of treatment increased whole-animal endurance capacity. A follow-up in Free Radical Biology and Medicine gave 26-month-old mice eight weeks of SS-31 and reversed age-related redox stress while improving exercise tolerance.

Now the part vendors leave out. Those same studies found little to no effect in young healthy animals, which is mechanistically logical and commercially inconvenient. And there is not a single completed human trial using healthy aging, healthspan, or performance in healthy adults as an endpoint. Not one. Everything in the anti-aging conversation about SS-31 is extrapolated from mice. Grade: animal-only.

Fatigue and Exercise Tolerance

Mechanistically this should work, and in aged mice it does. In humans the picture is muddier. The big mitochondrial myopathy trial measured fatigue directly and did not find a significant benefit at 24 weeks. Community reports describe a subtle, cumulative lift rather than a stimulant hit. Grade: animal-only for performance, anecdotal in humans.

Barth Syndrome and Mitochondrial Disease

The strongest human evidence, and the basis of the FDA approval. More on this below, because the detail matters. Grade: moderate clinical, approved on an intermediate endpoint.

Heart Health

Cardiac mitochondria are loaded with cardiolipin, and the animal data looked outstanding, including roughly 50% infarct size reduction in preclinical models. Then human trials ran. PROGRESS-HF found no improvement in heart failure, and EMBRACE-STEMI failed to reduce infarct size after heart attack. Grade: animal-only, human trials negative.

Kidney Protection

One of the better-looking early human signals. A small study published in Circulation: Cardiovascular Interventions gave SS-31 to 14 patients undergoing renal artery stenting and found increased renal blood flow and improved kidney function versus baseline. Fourteen people is fourteen people, but the direction is encouraging and it is backed by deep animal data. Grade: preliminary clinical.

Eye Health and Dry AMD

Photoreceptors are among the most energy-hungry cells you own, so the mitochondrial angle is sensible. The ReCLAIM-2 trial missed its primary endpoints but produced an interesting secondary signal around preservation of the ellipsoid zone, a retinal layer packed with mitochondria. Grade: preliminary and mixed.

Claims we would not put our name on: that SS-31 treats neurodegeneration, reverses skin aging, fixes insulin resistance, or improves liver disease in humans. Those are mechanistic guesses and animal work, nothing more.

What the Clinical Trials Showed

Most SS-31 articles cite the wins and quietly skip the losses. That is a mistake, because the failures tell you more about who this compound helps than the successes do.

The Barth Syndrome Story

Barth syndrome is an ultra-rare genetic disease affecting roughly 150 people in the United States, mostly boys. The cause is a mutation in the tafazzin gene, and here is why it matters for this article: tafazzin is the enzyme that remodels cardiolipin. Barth syndrome is, at its core, a cardiolipin disease.

So a cardiolipin-binding peptide is more mechanistically justified here than anywhere else in medicine. This is SS-31 aimed at the exact problem it was built for.

The TAZPOWER trial enrolled twelve patients. The randomized crossover portion failed both primary endpoints, which would normally end the story. But the open-label extension, where patients stayed on the drug for years, told a different one. Results published in Genetics in Medicine showed six-minute walk distance improving by 96 meters at week 168 and 123 meters at week 192, along with meaningful gains in knee extensor strength. The lesson appears to be that this drug needs a long runway, longer than a typical trial window allows.

The FDA combined that extension data with a natural-history control study and granted accelerated approval on September 19, 2025. Muscle strength served as the intermediate endpoint. A confirmatory trial is still required, and accelerated approvals can be withdrawn if it fails.

The Myopathy Trial That Failed

MMPOWER-3 is the one nobody quotes. It was the big one: 218 patients with primary mitochondrial myopathy, 24 weeks, 40 mg daily. Published in Neurology, it missed both co-primary endpoints. The six-minute walk difference was negative 3.2 meters with a p-value of 0.69, and the fatigue score showed nothing. The paper carries Class I evidence that elamipretide does not improve those outcomes at 24 weeks in that population.

Buried in the data was something more useful. A subgroup with nuclear DNA mutations affecting the mtDNA replisome, particularly CPEO patients, did show a real walk-test benefit. That finding is now driving a follow-up trial. Failed trials with a live subgroup are how drug development usually works, and pretending the failure did not happen helps nobody.

The pattern across the whole program is worth naming plainly. SS-31 performs best where mitochondrial dysfunction is the primary driver of disease and where you give it enough time. It underperforms in acute settings and in mixed populations. That is a coherent story, not a failure of the compound.

SS-31 Dosage and Protocols

People search for SS-31 dosage constantly, so this section summarizes what was used in clinical trials, what the FDA label specifies, what preclinical work used, and what communities discuss. It is informational. It is not a personal dosing recommendation, and none of it is approved dosing outside of Barth syndrome.

The number to know is 40 mg. That is the dose used across MMPOWER-2, MMPOWER-3, TAZPOWER, and ReCLAIM-2, given as a once-daily subcutaneous injection. It is also the FORZINITY label dose for patients over 30 kilograms. When trials wanted intravenous delivery, as in the heart and kidney studies, they used roughly 0.05 mg/kg per hour by infusion.

Notice the gap in that table. Community protocols run far below the 40 mg used in every human trial, and nobody has run a study validating those lower doses for anything. People landed there through cost, caution, and copying each other. That is not a criticism so much as a fact worth knowing before you assume online protocols are evidence-based.

Route matters too. Subcutaneous injection is the dominant route in trials and in practice. Oral SS-31 has no meaningful human efficacy evidence, which is unsurprising given what digestion does to peptides. Nasal SS-31 has no meaningful evidence either. If a vendor is selling you oral SS-31 with big promises, that promise is not backed by anything.

One more trap: vial size is not dose. A 10 mg vial reconstituted with different volumes of bacteriostatic water gives you completely different amounts per unit on the syringe. Know your vial’s total milligrams, know your reconstitution volume, and do the math before you draw. This is where most dosing mistakes happen.

Timing patterns in the community lean toward morning dosing, and cycles typically run 8 to 12 weeks. Trial dosing was continuous daily use rather than cycled, so the cycling convention is a community habit rather than a research finding.

SS-31 Side Effects and Safety

The safety picture is one of the better arguments for SS-31, and it is unusually well documented because the compound went through real trials with real monitoring.

Injection-site reactions dominate. Redness, itching, pain, and firmness at the injection site are the most common adverse events by a wide margin, and in the Barth cohort local reactions were near-universal with daily dosing. They are mild to moderate and manageable with site rotation.

The FORZINITY label flags eosinophilia, an increase in a type of white blood cell, with use beyond 30 days. It tends to peak around 90 days and resolve, and it is usually asymptomatic, but it is the kind of thing worth knowing if you plan long runs. The label also warns about hypersensitivity reactions and contains benzyl alcohol, making it inappropriate for neonates.

The reassuring part comes from MMPOWER-3. Across 218 patients over 24 weeks there were no deaths and no hospitalizations attributed to the drug, with 94% of participants completing the study. Discontinuation due to adverse events ran 7.3% on elamipretide versus 1.8% on placebo. For a daily injectable, that is a clean record.

The bigger risk for most readers is not the peptide. It is the vial. Research-grade material carries risks that trials do not: wrong identity, wrong concentration, endotoxins, poor sterility, and degradation from bad storage or shipping. A peptide that is engineered to concentrate 5,000-fold inside your mitochondria is not something you want contaminated. Buying from a vendor with third-party testing and a posted Certificate of Analysis is the single highest-leverage safety decision you can make here.

Who Should Avoid SS-31

Anyone pregnant or breastfeeding, since no safety data exists. Children and adolescents outside the approved Barth indication. Anyone with a history of severe allergic reactions to peptide therapies. And anyone in a tested sport should verify status with their governing body before touching an injectable performance-adjacent peptide. Theoretical concerns around cancer and mitochondrial overstimulation get raised online but have not been demonstrated in the trial record either way.

Is SS-31 Legal? Regulatory Status

In the United States, elamipretide is FDA-approved as FORZINITY for Barth syndrome in patients weighing at least 30 kilograms, granted September 19, 2025 under accelerated approval. It carries Orphan Drug, Fast Track, Priority Review, and Rare Pediatric Disease designations. The path was not smooth: the FDA issued a Complete Response Letter first, and an advisory committee voted 10 to 6 in favor before approval followed.

That is the entire scope of approval anywhere. SS-31 is not approved for mitochondrial disease generally, fatigue, aging, heart disease, kidney injury, eye disease, or performance. In the EU, elamipretide holds an orphan designation for Barth syndrome granted in 2021, which is a development incentive rather than a marketing authorization. The UK, Canada, and Australia have no approval on record.

Research-grade SS-31 is sold for laboratory use only. It is not an approved drug and it is not a dietary supplement ingredient, so it cannot be legally marketed for human treatment. Selling it with claims about energy, aging, or performance is exactly what the FTC exists to punish.

Four phrases people treat as synonyms and should not: “available online,” “legal to possess,” “FDA-approved,” and “clinically proven.” SS-31 manages to sit in an unusual spot where the molecule is truly approved for one disease while the product most people buy is none of those other things.

SS-31 vs MOTS-c, NAD+, CoQ10, and MitoQ

Everything in the mitochondrial aisle claims to support your mitochondria. They are not doing the same job, and the differences are easy to see once you know what each one targets.

The cleanest way to think about it: NAD+ precursors supply fuel for the reactions. CoQ10 and MitoQ manage electrons and oxidation. PQQ nudges you to build more mitochondria. Creatine buffers ATP outside the mitochondria entirely. SS-31 is the only one repairing the structural wiring the whole system is mounted on. It is also the only one whose molecule cleared the FDA.

SS-31 does not replace approved medical treatment for any condition, and it is not competing with creatine for the same job. These are different tools.

What People Stack With SS-31

Describing what people do, not telling you to do it. The honest headline is that not a single one of these combinations has a human trial behind it.

The most popular pairing is SS-31 with MOTS-c, usually framed as hardware plus software: one repairs the membrane structure, the other signals metabolic adaptation. After that come the mitochondrial support stacks, SS-31 with NAD+ precursors, CoQ10, PQQ, or MitoQ, on the logic that fixing the wiring works better when the coenzymes and electron carriers are topped up. Some people add creatine for ATP buffering, and plenty pair it with the boring stuff that builds mitochondria: Zone 2 cardio, resistance training, red light, and sleep.

The caution is the same for all of them. Stack four mitochondrial compounds at once and you will never know which one did anything, and if something goes sideways you will not know what caused it. Run it alone for a cycle first. And no stack outruns bad sleep and no training.

What Users Report

Anecdotal, drawn from peptide and longevity communities, and not evidence. It is still useful for setting expectations.

The most consistent theme is that SS-31 is not a stimulant and does not feel like one. People describe a slow, cumulative lift in baseline energy that they usually notice around week three or four, not day one. The two most-reported wins are faster recovery between training sessions and better cognitive stamina deep into long work. Nobody describes a rush.

The other side is equally consistent. A meaningful share of people report nothing at all, which lines up neatly with the mechanism: if your mitochondria are not dysfunctional, there may be nothing to repair. Injection-site irritation is the common complaint. And the community consensus is that sourcing is the biggest variable in whether anyone gets anything out of it.

Worth knowing: forums constantly confuse SS-31 with pharmaceutical elamipretide and treat the Barth approval as blanket validation for taking it at 5 mg a day for energy. It is not. Read community threads with that filter on.

Where to Buy SS-31

SS-31 sits in research-compound territory, which means the vendor is doing the quality control that a pharmacy would otherwise do. There is no regulator standing between you and a bad vial.

What to demand: independent third-party testing from a named lab, a Certificate of Analysis you can see before purchase, clearly stated vial contents in milligrams, proper cold-chain handling, and a vendor with a traceable track record. Red flags: no COA, a COA that does not match your batch, vague sourcing answers, oral SS-31 sold with injection-level promises, and any seller marketing it as a treatment for a disease.

Everest Peptides is where we point BrainFlow readers for SS-31. Their material is third-party tested by Freedom Diagnostics, an independent lab you can look up, with the Certificate of Analysis posted so you can verify identity and purity before you buy rather than hoping after the fact. The vial is regularly $49.99 and is on sale at $44.99, and code BRAINFLOW takes another 10% off that sale price, which lands you around $40.

The testing is the reason we recommend them, not the price. With a peptide engineered to concentrate thousands of times over inside your mitochondria, “probably fine” is not an acceptable standard for what is in the vial.

Frequently Asked Questions

Is SS-31 FDA approved?

The molecule is, under the name FORZINITY (elamipretide), approved September 19, 2025 for Barth syndrome in patients over 30 kilograms. That is the only approval anywhere. SS-31 is not approved for aging, fatigue, performance, heart disease, or eye disease, and research-grade SS-31 sold online is not the approved pharmaceutical.

What is the difference between SS-31 and elamipretide?

They are the same molecule. SS-31 is the research name, elamipretide is the pharmaceutical name, and MTP-131 and Bendavia are older development codes. The difference is manufacturing standards, testing, and legal status, not chemistry.

What does SS-31 do?

It binds cardiolipin in the inner mitochondrial membrane, stabilizing the structure that holds your energy-producing machinery together. That improves ATP output and reduces reactive oxygen species in mitochondria that are dysfunctional.

How long does SS-31 take to work?

In aged mice, mitochondrial energetics improved within an hour of a single dose. In humans, community reports describe a cumulative effect noticed around three to four weeks, and the Barth trial data suggests the real gains took months to accumulate.

What is the standard SS-31 dosage?

Every major human trial and the FDA label use 40 mg once daily by subcutaneous injection. Community protocols typically run much lower, around 5 to 10 mg daily, with no trial data supporting those doses.

Does SS-31 work for anti-aging?

In aged mice, impressively so. In humans, no completed trial has ever tested healthy aging or performance as an endpoint, so anyone claiming proof is extrapolating from rodents.

Is SS-31 safe?

Trial safety has been good, with injection-site reactions the dominant issue and no deaths or hospitalizations across 218 patients in the largest study. Long-term safety at wellness doses is unknown, and product quality is the bigger practical risk with research-grade material.

SS-31 vs MOTS-c, which is better?

They do different jobs. SS-31 repairs mitochondrial membrane structure and has real clinical trials behind it. MOTS-c is a signaling peptide affecting metabolic pathways with mostly preclinical data. Neither replaces the other.

Where can I buy SS-31?

BrainFlow points readers to Everest Peptides SS-31, third-party tested by Freedom Diagnostics with the Certificate of Analysis posted before purchase. Regularly $49.99, on sale at $44.99, and code BRAINFLOW takes another 10% off the sale price for roughly $40.

The Bottom Line on SS-31

SS-31 is the most mechanistically precise peptide in the longevity world, and it is the only one whose molecule has an FDA approval attached to it. Those two facts put it in a category of one. When a compound concentrates thousands of times over at a single membrane and repairs the specific lipid that organizes your energy machinery, that is not “mitochondrial support.” That is engineering.

The trial record is more complicated than the marketing, and we would rather you hear it here than find out later. Several large studies missed. The approval is narrow and conditional. Nobody has tested this in healthy people for energy or performance, and the animal work that excites everyone showed the biggest effects in old animals and almost nothing in young ones.

What that adds up to is a compound with a real future and a specific profile. If your mitochondria are struggling, SS-31 is aimed at the actual problem in a way nothing on a supplement shelf is. If everything is running fine, expect less. The people reporting the best results are running it long enough to matter and sourcing material they can verify.

If you are going to run it, get it from somewhere that proves what is in the vial. Everest Peptides SS-31 is third-party tested by Freedom Diagnostics with a posted COA, on sale at $44.99 from $49.99, and code BRAINFLOW takes another 10% off for about $40. With a peptide this targeted, knowing exactly what you are injecting is not a nice-to-have.

Shop SS-31 at Everest Peptides (code BRAINFLOW saves another 10%)

SS-31 is not FDA-approved for any indication other than elamipretide (FORZINITY) for Barth syndrome. All information here is for educational and research purposes only and is not medical advice.

SS-31 is sold as a research compound for laboratory use only. Consult a qualified healthcare provider before beginning any protocol.

This article contains affiliate links. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.